Skip to search formSkip to main contentSkip to account menu

Cilomilast

Known as: 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1- carboxylic acid, Cilomilast [Chemical/Ingredient], Cis-4-Cyano-4-(3-(Cyclopentyloxy)-4-Methoxyphenyl)Cyclohexanecarboxylic Acid 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ArifloSB 207499

Broader (3)

Cyclohexanecarboxylic AcidsNitrilesPhosphodiesterase 4 Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Doxofylline does not increase formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of anti-inflammatory effect.
2010
2010
Pharmacological studies of bronchial constriction inhibited by parasympatholytics and cilomilast using equine precision-cut lung slices.
Equine precision cut lung slices (PCLS) were used to evaluate the ability of several pharmacologic compounds, parasympatholytics… 
2005
2005
Potentiation and prolongation of long-term odor memory in neonate rats using a phosphodiesterase inhibitor
2005
2005
CGH2466, a combined adenosine receptor antagonist, p38 mitogen‐activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti‐inflammatory activities
1 Theophylline, a phosphodiesterase inhibitor and adenosine receptor antagonist, is used in asthma and chronic obstructive… 
2005
2005
Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD
Cilomilast is a highly selective, orally active phosphodiesterase (PDE)4 inhibitor currently under evaluation for the treatment… 
Review
2002
Review
2002
Phosphodiesterase 4 inhibitors for the treatment of COPD.
Phosphodiesterase 4 (PDE4) is a major cyclic adenosine-3',5'-monophosphate-metabolizing enzyme in immune and inflammatory cells… 
2002
2002
Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
We investigated the safety and potential pharmacodynamic interactions arising from the co-administration of inhaled beta(2… 
2002
2002
Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… 
2001
2001
Bioavailability of the Oral Selective Phosphodiesterase 4 Inhibitor Cilomilast
Study Objective. To determine the absolute bioavailability of cilomilast, and assess the effects of food, dosing time, and… 
2001
2001
Warfarin Pharmacodynamics Unaffected by Cilomilast
OBJECTIVE: To demonstrate a lack of effect of steady-state concentrations of cilomilast, a new oral phosphodiesterase 4 inhibitor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)